New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:40 EDTTKPPY, NVO, ARMHBarclays to hold a conference
European Select Conference to be held in San Francisco on June 19.
News For ARMH;NVO;TKPPY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
05:28 EDTARMHARM announces the acquisition of Wicentric and Sunrise Micro Devices
ARM announced the acquisition of Wicentric, a Bluetooth Smart stack and profile provider, and Sunrise Micro Devices, a provider of sub-one volt Bluetooth radio intellectual property. Terms of the agreements have not been disclosed. The IP of both companies will be integrated to form the ARMŽ Cordio portfolio. The ARM Cordio portfolio is available for immediate licensing.
05:13 EDTTKPPYTechnip awarded FEED contract for Liuhua fields in South China Sea
Subscribe for More Information
April 15, 2015
11:55 EDTNVONovo Nordisk initiated with a Sell at Societe Generale
Subscribe for More Information
07:41 EDTNVOEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
05:12 EDTTKPPYTechnip awarded subsea contract on Triton FPSO
Technip has been awarded a brownfield subsea contract for the Triton floating production storage and offloading, or FPSO, vessel, operated by Dana Petroleum, located in the central North Sea. This FPSO vessel is located 193 kilometers east of Aberdeen, at a water depth of approximately 90 meters. It produces oil and gas from different fields - Bittern, Guillemot West and North West, Clapham, Pict and Saxon, which are tied back to the FPSO vessel via subsea facilities comprising a series of pipelines and manifolds.
April 9, 2015
05:58 EDTARMHARM spikes on rumors of Apple deal, Telegraph reports
Subscribe for More Information
April 8, 2015
10:45 EDTARMHHigh option volume stocks
Subscribe for More Information
April 7, 2015
15:44 EDTNVONovo Nordisk announces FDA accepts Tresiba, Ryzodeg resubmissions for review
Novo Nordisk announced that the U.S. FDA has accepted for review the Class II Resubmissions for Tresiba and Ryzodeg. To preserve the integrity of the ongoing DEVOTE trial, only a small team within Novo Nordisk has access to the data. This team has prepared the interim analysis for the Class II resubmission and will interact with the FDA during the review, on matters related to the interim analysis. As previously communicated, the result of an interim analysis carries a higher level of uncertainty than the final study results as this preliminary estimate is built on a substantially lower number of observations. Accordingly, the relative risk estimate derived from the interim analysis is thus only an indication of the final trial results. Novo Nordisk management does not have access to the results of the interim analysis. The trial is expected to be completed in the second half of 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use